César Serrano, Xavier García-del-Muro, Claudia Valverde, Ana Sebio, José Durán, Aránzazu Manzano, Isabel Pajares, Nadia Hindi, Stefania Landolfi, Laura Jiménez, Jordi Rubió-Casadevall, Anna Estival, Javier Lavernia, María José Safont, Carles Pericay, Roberto Díaz-Beveridge, Virginia Martínez-Marín, David Vicente-Baz, Ana Vivancos, Javier Hernández-Losa, Joaquín Arribas, Joan Carles. Clinicopathological and molecular characterization of metastatic gastrointestinal stromal tumors patients with prolonged benefit to frontline imatinib.
The Oncologist, August 2018. doi: 10.1634/theoncologist.2018-0032.
Javier Martin-Broto, Nadia Hindi, Josefina Cruz, Javier Martinez-Trufero, Claudia Valverde, Luis M De Sande, Angeles Sala, Laura Bellido, Ana De Juan, Isabel Sevilla, Jordi Rubió, Roberto Diaz, Ricardo Cubedo, Oscar Tendero, Diego Salinas, Isidro Gracia, Rafael Ramos, Silvia Baguè, Antonio Gutierrez, José Duran-Moreno and Antonio Lopez-Pousa. Relevance of reference centers in sarcoma care and quality item evaluation: results from the prospective registry of the Spanish group for research in sarcoma (GEIS).
The Oncologist 2018;23:1–9. http://dx.doi.org/10.1634/theoncologist.2018-0121.
Alemany R., Moura D.S., Redondo A., Martinez-Trufero J., Calabuig S., Saus C., Obrador-Hevia A., Ramos R., Villar V.H., Valverde C., Vaz M.A., Medina J., Felipe-Abrio I., Hindi N., Taron M, Martin-Broto J. Nilotinib as co-adjuvant treatment with doxorubicin in patients with sarcomas: A phase I trial of the Spanish Group for Research on Sarcoma.
Clin Cancer Research July 23, 2018. doi.org/10.1158/1078-0432.CCR-18-0851.
Javier Martin-Broto,, Silvia Stacchiotti, Antonio Lopez-Pousa, Andres Redondo, Daniel Bernabeu, Enrique de Alava, Paolo G. Casali, Antoine Italiano, Antonio Gutierrez, David S. Moura, Maria Peña, Juan Diaz-Martin, Michelle Biscuola, Miquel Taron, Paola Collini, Dominique Ranchere-Vince, Xavier Garcia del Muro, Giovanni Grignani, Sarah Dumont, Javier Martinez-Trufero, Emanuela Palmerini, Nadia Hindi, Ana Sebio, Joaquin Dopazo, Axel LeCesne, Jean-Yves Blay and Josefina Cruz. Multi-institutional European single-arm phase II trial of Pazopanib in advanced malignant/dedifferentiated Solitary Fibrous Tumor (SFT). A Collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups Study.
(Lancet Oncology in submission).
Pasquali S, Colombo C, Pizzamiglio S, Verderio P, Callegaro D, Stacchiotti S, Martin Broto J, Lopez-Pousa A, Ferrari S, Poveda A, De Paoli A, Quagliuolo V, Jurado JC, Comandone A, Grignani G, De Sanctis R, Palassini E, Llomboart-Bosch A, Dei Tos AP, Casali PG, Picci P, Gronchi A. High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial.
Eur J Cancer. 2018 Apr; 93:28-36.
Kasper B, Lecointe-Artzner E, Wait S, Boldon S, Wilson R, Gronchi A, Valverde C, Eriksson M, Dumont S, Drove N, Kanli A, Wartenberg M. Working to improve the management of sarcoma patients across Europe: a policy checklist.
BMC Cancer. 2018 Apr 16;18(1):424. doi: 10.1186/s12885-018-4320-y.
David S Moura, Rafael Ramos, Antonio Fernandez-Serra, Teresa Serrano, Julia Cruz, Ramiro Alvarez-Alegret, Rosa Ortiz-Duran, Luis Vicioso, Maria Luisa Gomez-Dorronsoro, Xavier Garcia Del Muro, Javier Martinez-Trufero, Jordi Rubio-Casadevall, Isabel Sevilla, Nuria Lainez, Antonio Gutierrez, Cesar Serrano, Maria Lopez-Alvarez, Nadia Hindi, Miguel Taron, José Antonio López-Guerrero, Javier Martin-Broto. Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.
Oncotarget. 2018 Apr 3; 9(25): 17576–17588.
Xavier García Del Muro, Joan Maurel, Javier Martínez Trufero, Javier Lavernia, Antonio López Pousa, Ramón de Las Peñas, Ricardo Cubedo, José Pablo Berros, Antonio Casado Herráez, Ana de Juan, Javier Martín Broto. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
Invest New Drugs 2018 Jun 12;36(3):468-475. Epub 2018 Mar 12.
Juan Martin-Liberal, Antonio López-Pousa , Javier Martínez-Trufero , Javier Martín-Broto, Ricardo Cubedo, Javier Lavernia, Andrés Redondo, José Antonio López-Martín, Nùria Mulet-Margalef, Xavier Sanjuan, Òscar Martínez Tirado, Xavier García del Muro. Phase II study of gemcitabine plus sirolimus in previously treated patients with advanced soft-tissue sarcoma: a Spanish Group for Research on Sarcomas (GEIS) study.
Target Oncol. 2018 Feb;13(1):81-87.
J. Martin-Broto, V. Martinez-Martín, C. Serrano, N. Hindi, J. A. López-Guerrero, R. Ramos-Asensio, A. Vallejo-Benítez, D. Marcilla-Plaza, R. González-Cámpora.Gastrointestinal stromal tumors (GISTs): SEAP–SEOM consensus on pathologic and molecular diagnosis.
Clin Transl Oncol. DOI 10.1007/s12094-016-1581-2
Javier Martin-Broto, Antonio López Pousa, Ramón De las Peñas, Xavier Garcia del Muro, Antonio Gutierrez, Javier Martinez-Trufero, Josefina Cruz, Rosa Alvarez, Ricardo Cubedo, Andrés Redondo, Joan Maurel, Juan A Carrasco, Jose A López-Martin, Angeles Sala, Andrés Meana, Rafael Ramos, Jordi Martinez-Serra, Jose A Lopez-Guerrero, Isabel Sevilla, Carmen Balaña, Angeles Vaz, Ana de Juan, Regina Alemany and Andrés Poveda.Randomized Phase II Study Of Trabectedin And Doxorubicin Compared With Doxorubicin Alone As First Line Treatment In Patients With Advanced Soft Tissue Sarcomas: A Spanish Group For Research On Sarcoma (GEIS) Study.
J Clin Oncol. 2016 Jul 1;34(19):2294-302. doi: 10.1200/JCO.2015.65.3329
Joan Maurel, M.D.; Antonio Pousa López; Silvia Calabuig; Silvia Bague; Xavier Garcia del Muro; Xavier Sanjuan; Jordi Rubio Casadevall; Miriam Cuatrecasas; Javier Martínez Trufero; Carlos Horndler; Joaquin Fra; Claudia Valverde; Andrés Redondo; Andrés Poveda; Isabel Sevilla; Nuria Lainez; Michele Rubini; Xavier García Albéniz; Javier Martin Broto; Enrique de Álava.Phosphorylated-Insulin Growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study.
Clin Sarcoma Res. 2016 Jun 29;6:10
Garcia del Muro X, de Alava E, Artigas V, Bague S, Braña A, Cubedo R, Cruz J, Mulet-Margalef N, Narvaez JA, Martinez Tirado O, Valverde C, Verges R, Viñals J, Martin-Broto J; Spanish Group for Research on Sarcoma.Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS).
Cancer Chemother Pharmacol. 2016 Jan;77(1):133-46. doi: 10.1007/s00280-015-2809-5
López-Pousa A, Martin Broto J, Martinez Trufero J, Sevilla I, Valverde C, Alvarez R, Carrasco Alvarez JA, Cruz Jurado J, Hindi N, Garcia Del Muro X. SEOM Clinical Guideline of management of soft-tissue sarcoma (2016).
Clin Transl Oncol. 2016 Dec;18(12):1213-1220
Martín-Broto J, Hindi N. Targeted treatments of sarcomas and connective tumors beside gastrointestinal stromal tumor.
Curr Opin Oncol. 2016; 28 (4): 338-44.
Rubió-Casadevall J, Borràs J, Carmona-García M, Ameijide A, Gonzalez-Vidal A, Ortiz M, Bosch R, Riu F, Parada D, Martí E, Miró j, Sirvent J, Galceran J, Marcos-Gragera R Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors: a population-based study World J Surg Oncol.
2015 Dec;13(1):474. doi:10.1186/s12957-015-0474-0. Epub 2015 Feb 13.
Martín Broto J, Gutiérrez A, Ramos R, López Guerrero JA, Ferrari S, Stachiotti S, Picci P, Calabuig S, Collini P, Gambarotti M, Bagué S, Dei Tos AP, Palassini E, Luna P, Cruz J, Cubedo R, Martínez Trufero J, Poveda A, Casali P, Fernández Serra A, López Pousa A, Gronchi A MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS study.
Mol Cancer Ther. 2014 Jan;13(1):249-59. doi: 10.1158/1535-7163.MCT-13-0406. Epub 2013 Oct 21.
Martín Liberal J, López Pousa A, Martín Broto J, Cubedo R, Gallego O, Brendel E, Martínez Tirado O, García del Muro X Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.
Invest New Drugs. 2014 Apr;32(2):287-94. doi: 10.1007/s10637-013-9989-9. Epub 2013 Jun 26.
Jordi Rubió-Casadevall MD, Javier Martinez-Trufero MD, Xabier Garcia-Albeniz MD, Silvia Calabuig MD, Antonio Lopez-Pousa MD, Javier Garcia del Muro MD, Joaquin Fra MD, Andrés Redondo MD, Nuria Lainez MD, Andrés Poveda MD, Claudia Valverde MD, Ana De Juan MD, Isabel Sevilla MD, Antonio Casado MD, Raquel Andres MD, Josefina Cruz MD, Javier Martin-Broto MD, Joan Maurel MD, the Spanish Group for Research on Sarcoma (GEIS) GEIS-16 en Annals of Surgical Oncology Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS).
Annals of Surgical Oncology 2015 Jan 22
A Poveda, X García del Muro, JA López Guerrero, V Martínez, I Romero, C Valverde, R Cubedo and J Martín Broto. GEIS 2013 guidelines for gastrointestinal sarcomas (GIST) Cancer Chemother Pharmacol; 2014 Sep DOI 10.1007/s00280-014-2547-0 PMID: 25193432.
Published online. IF: 2.751
Martín-Liberal J, López-Pousa A, Broto JM, Cubedo R, Gallego O, Brendel E, Tirado OM, Del Muro XG. Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.
Invest New Drugs. 2014 Apr;32(2):287-94. PMID:23801301, IF: 3.4
Fuster D, Ayuso JR, Poveda A, Cubedo R, Casado A, Martínez-Trufero J, López-Pousa A, Del Muro XG, Lomeña F, Maurel J, Pons F. Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study.
Q J Nucl Med Mol Imaging. 2011 Dec;55(6):680-7. PMID:21150863. IF: 1.9
Xavier García-del-Muro, Antonio López-Pousa, Joan Maurel, Javier Martín, Javier Martínez-Trufero, Antonio Casado, Auxiliadora Gómez-España, Joaquín Fra, Josefina Cruz, Andrés Poveda, Andrés Meana, Carlos Pericay, Ricardo Cubedo, Jordi Rubió, Ana De Juan, Nuria Laínez, Juan Antonio Carrasco, Raquel de Andrés, and José M. Buesa. Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study.
J Clin Oncol. 2011 Jun 20;29(18):2528-33. doi: 10.1200/JCO.2010.33.6107.
Poveda A, Artigas V, Casado A, Cervera J, García del Muro X, López-Guerrero JA, López-Pousa A, Maurel J, Ortega L, Ramos R, Romero I, José Safont M and Martín J. Guías de la práctica Clínica en los tumores estromales grastrointestinales (GIST): actualización 2008.
Cirugía Española. 2008; 84(1):1-21. PMID:19087862. IF: 0.8
J Martin; A Gutierrez; J Garcia del Muro; J Maurel; JL González de Sande; J Martinez; A de Juan; N Lainez , F Losa and A Poveda. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST.
A Spanish Group for Sarcoma Research (GEIS) Study PMID:20231303, IF: 7.3.
Maurel J, López-Pousa A, de Las Peñas R, Fra J, Martín J, Cruz J, Casado A, Poveda A, Martínez-Trufero J, Balañá C, Gómez MA, Cubedo R, Gallego O, Rubio-Viqueira B, Rubió J, Andrés R, Sevilla I, de la Cruz JJ, Del Muro XG, Buesa JM. Efficacy of Sequential High-Dose Doxorubicin and Ifosfamide Compared With Standard-Dose Doxorubicin in Patients With Advanced Soft Tissue Sarcoma: An Open-Label Randomized Phase II Study of the Spanish Group for Research on Sarcomas.
Journal of Clinical Oncology. Marzo 2009. PMID: 19273704. IF: 18.3
López-Pousa A, Losa R, Martín J, Maurel J, Fra J, Sierra M, Casado A, García del Muro X, Poveda A, Balaña C, Martínez-Trufero J, Esteban E, Buesa JM. Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study.
British Journal of Cancer (2006), 1 –6. Jun 19;94(12):1797-802. PMID:16721358. IF: 5.0
Buesa JM, Fra J, Antón A, López-Pousa A, Martín J, García del Muro X, Escudero P, Casado A, Poveda A. Activity of doxorubicin after high-dose ifosfamide in adult patients with advanced soft tissue sarcoma: a study of the Spanish Group for Research on Sarcomas (GEIS).
Ann Oncol. 1998 Jul;9(7):783-5. PMID: 9739447. IF: 7.3
Poveda A, Rivera F, Martín J.SEOM guidelines for gastrointestinal stromal sarcoma (GIST).
Clinical & Translational Oncology. 2012; 14(7):536-540.PMID:22721799. IF: 1.2
García Del Muro X, Martín J, Maurel J, Cubedo R, Bagué S, de Álava E, Pousa AL, Narváez JA, Ortiz E, Pomés J, Poveda A, Romasanta LP, Tendero O, Viñals JM; Grupo Español de Investigación en Sarcomas (GEIS). Soft tissue sarcomas: clinical practice guidelines.
Med Clin (Barc). 2011 Apr 9;136(9):408.e1-8. PMID:21411112. IF: 1.3
Guías de la práctica Clínica en GIST Clinical & Translational Oncology”, vol. 7, Ext. 2, 2005
Cirugía Española, vol. 84, Ext. 1 / Clinical & Translational Oncology 2008-1. IF:1.2
Losa R, Fra J, López-Pousa A, Sierra M, Goitia A, Uña E, Nadal R, García del Muro X, Gión M, Maurel J, Escudero P, Esteban E, Buesa JM. Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas.
Cancer Chemother Pharmacol. DOI 10.1007/s00280-006-0263-0 May 2006. PMID:16736150 [PubMed - indexed for MEDLINE]. IF: 2.7
López-Pousa A, Martín J, García del MuroX, Bernabé R, Casado A, Balañá C, Sanmartín O, Menéndez MD, Escudero P, Cruz J, Belyakova E, Menéndez D, Buesa JM. Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult. A study of the Spanish Group for Research in Sarcomas (GEIS).
Sarcoma volumen 9 (2005): 127-132. PMID:18521419. IF:1.22
Poveda A, López-Pousa A, Martín J, Montalar J, de las Peñas, R, García del Muro X, Cruz J, Maurel J, Escudero P, Casado A, Buesa JM, Martínez-Trufero J, Bover I, Sevilla I, Balañá C, Paredes A, Carles J, Vicent J, Cassinello J. Phase II clinical trial with pegylated liposomal doxorubicin (Caelyx®) / Doxil®) and quality of life evaluation (EORTC QLQC30) in adult patients with advanced soft tissue sarcomas. A Study of the Spanish Group for Research on Sarcomas (GEIS).
Sarcoma. Volume 2006; Article ID 26986, Pages 1-8. PMID:17251655. IF:1.22
Martín J, Poveda A, Llombart-Bosch A, Ramos R, López-Guerrero JA, García del Muro X, Maurel J, Calabuig S, Gutierrez A, González de Sande JL, Martínez-Trufero J, de Juan A, Laínez N, Losa F, Alija V, Escudero P, Casado A, García P, Blanco R, Buesa JM. Deletions Afecting Codons 557-558 of the c-KIT Gene Indicate a Poor Prognosis in Patients With Completely Resected Gastrointestinal Stromal Tumors: A Study by the Spanish Group for Sarcoma Research (GEIS).
J Clin Oncol. 2005 Sep 1;23(25):6190-8.PMID: 16135486. IF: 18.37
García del Muro X, López-Pousa A, Martín J, Buesa JM, Martínez-Trufero J, Casado A, Poveda A, Cruz J, Bover I, Maurel J. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
Cancer. 2005 Aug 30;104(8):1706-12. PMID: 16134177. IF: 5.2
Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, Gronchi A, Hogendoorn PC, Joensuu H, Le Cesne A, McClure J, Maurel J, Nupponen N, Ray-Coquard I, Reichardt P, Sciot R, Stroobants S, van Glabbeke M, van Oosterom A, Demetri GD. Consensus meeting for the management of gastroinstestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.
Ann Oncol. 2005 Apr;16(4):566-78. PMID: 15781488. IF: 7.3
Maurel J, Buesa JM, López-Pousa A, García del Muro X, Quintana MJ, Martín J, Casado A, Martínez-Trufero J, de las Peñas R, Balañá C. Salvage surgical resection after high-dose ifosfamide (hdif) based regimens in advanced soft tissue sarcoma (asts): a potential positive selection bias – a studi of Spanish group for research on sarcomas (GEIS).
J Surg Oncol. 2004 Oct 1;88(1):44-9. PMID: 15384088. IF:2.5
Maurel J, Fra J, López-Pousa A, García del Muro X, Balañá C, Casado A, Martín J, Martínez-Trufero J, de las Peñas R, Buesa JM; Spanish Group for Research on Sarcomas (GEIS). Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Cancer. 2004 Apr 1;100(7):1498-506. PMID: 15042685. IF: 5.2
Buesa JM, Losa R, Fernández A, Sierra M, Esteban E, Díaz A, López-Pousa A, Fra J. Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation.
Cancer. 2004 Nov 15;101(10):2261-9. PMID: 15484216 IF: 5.2
Buesa JM, Teijido PG, Losa R, Fra J. Treatment of Ifosfamide Encephalopathy with Intravenous Thiamin.
Clinical Cancer Resarch. 2003 Oct 9:4636-7. IF: 7.83
Buesa JM, López-Pousa A, Martín J, Antón A, García del Muro X, Bellmunt J, Arranz F, Valenti V, Escudero P, Menéndez D, Casado A, Poveda A.Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS).
Ann Oncol. 1998 Aug;9(8):871-6. PMID: 9789610. IF: 7.3